Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Astellas Pharma : Announces Sale of Certain Agensys Research Facilities to Kite, a Gilead Company

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/23/2018 | 10:33am CEST

TOKYO - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, 'Astellas' ) and Kite, a Gilead Company (Nasdaq: GILD, President and CEO: John Milligan, 'Kite') today announced that an agreement has been completed for the transfer of certain Agensys research facilities in Santa Monica, California, USA, to Kite.

The asset transfer was completed on April 12, 2018. Additional financial information or further deal terms are not being disclosed.

The facilities transfer is part of the wind-down process of the Agensys research operations, as announced by Astellas on July 27, 2017. Additional wind-down activities were completed in the first quarter of calendar year 2018, following the Company's decision to further refine its oncology strategy by expanding its investment in the research in new technologies and modalities and reducing its focus on Antibody-Drug Conjugate (ADC) research, which was the core focus of work conducted at Agensys. Astellas will continue certain clinical trials and collaborations on some ADC programs that have been in progress at Agensys, including its collaboration with Seattle Genetics, Inc.

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients.

About Gilead Sciences

Kite, a Gilead Company, is a biopharmaceutical company based in Santa Monica, California. Kite is engaged in the development of innovative cancer immunotherapies. The company is focused on chimeric antigen receptor and T cell receptor engineered cell therapies.

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Astellas Cautionary Notes

In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forwardlooking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.

Gilead Forward-Looking Statements

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility that the closing conditions may not be satisfied and the transaction may not be completed. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include risks and uncertainties detailed from time to time in Gilead Sciences, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements.

Contact:

Tel: +81-3-3244-3201

(C) 2018 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
04/23ASTELLAS PHARMA : Announces Sale of Certain Agensys Research Facilities to Kite,..
AQ
04/23GILEAD SCIENCES : to Release First Quarter 2018 Financial Results on Tuesday, Ma..
AQ
04/21ASTELLAS PHARMA : sells certain U.S. research facilities to Gilead
AQ
04/20GILEAD SCIENCES : Non-profit KEI sues NIH to block Gilead's anti-CD30 CAR T pate..
AQ
04/19GILEAD SCIENCES : Research Conducted at Gilead Sciences Inc. Has Provided New In..
AQ
04/19GILEAD SCIENCES : New Hepatitis C Virus Data Have Been Reported by Investigators..
AQ
04/19GILEAD SCIENCES : Study Results from Gilead Sciences Broaden Understanding of HI..
AQ
04/19GILEAD SCIENCES : Tmunity tops off series A round
AQ
04/19GILEAD SCIENCES : Astellas Announces Sale of Certain Agensys Research Facilities..
PR
04/17GILEAD SCIENCES : to Release First Quarter 2018 Financial Results on Tuesday, Ma..
BU
More news
News from SeekingAlpha
01:42aJF'S CORE BIOTECH BUYS #12 : Updates And Introducing Our 18th Selection 
04/23The More It Drops, The More I Buy - Part 3 
04/23How To Retire At 65 With Only Half A Million 
04/23GILEAD : Will Medicare Boost Yescarta Sales? 
04/20PORTFOLIO STRATEGY REPORT : Why Investors Should Build Shares In Bioscience Stoc.. 
Financials ($)
Sales 2018 21 295 M
EBIT 2018 11 197 M
Net income 2018 6 715 M
Debt 2018 17 121 M
Yield 2018 3,06%
P/E ratio 2018 14,16
P/E ratio 2019 13,38
EV / Sales 2018 5,32x
EV / Sales 2019 5,45x
Capitalization 96 094 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 89,0 $
Spread / Average Target 20%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Chairman
Robin L. Washington CFO, Principal Accounting Officer & Executive VP
Norbert W. Bischofberger CSO, Executive VP-Research & Development
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES2.88%96 094
VERTEX PHARMACEUTICALS5.53%40 153
REGENERON PHARMACEUTICALS-16.41%33 844
GENMAB23.13%12 797
BEIGENE LTD (ADR)71.91%8 998
BLUEBIRD BIO INC-5.53%8 522